IBDEI1C4 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21574,1,3,0)
 ;;=3^Sicca Syndrome w/ Myopathy
 ;;^UTILITY(U,$J,358.3,21574,1,4,0)
 ;;=4^M35.03
 ;;^UTILITY(U,$J,358.3,21574,2)
 ;;=^5011789
 ;;^UTILITY(U,$J,358.3,21575,0)
 ;;=M35.09^^70^921^57
 ;;^UTILITY(U,$J,358.3,21575,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21575,1,3,0)
 ;;=3^Sicca Syndrome w/ Oth Organ Involvement
 ;;^UTILITY(U,$J,358.3,21575,1,4,0)
 ;;=4^M35.09
 ;;^UTILITY(U,$J,358.3,21575,2)
 ;;=^5011791
 ;;^UTILITY(U,$J,358.3,21576,0)
 ;;=M35.04^^70^921^58
 ;;^UTILITY(U,$J,358.3,21576,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21576,1,3,0)
 ;;=3^Sicca Syndrome w/ Tubulo-Interstitial Nephropathy
 ;;^UTILITY(U,$J,358.3,21576,1,4,0)
 ;;=4^M35.04
 ;;^UTILITY(U,$J,358.3,21576,2)
 ;;=^5011790
 ;;^UTILITY(U,$J,358.3,21577,0)
 ;;=M35.00^^70^921^59
 ;;^UTILITY(U,$J,358.3,21577,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21577,1,3,0)
 ;;=3^Sicca Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,21577,1,4,0)
 ;;=4^M35.00
 ;;^UTILITY(U,$J,358.3,21577,2)
 ;;=^5011786
 ;;^UTILITY(U,$J,358.3,21578,0)
 ;;=M32.10^^70^921^62
 ;;^UTILITY(U,$J,358.3,21578,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21578,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec Organ/System Involvement
 ;;^UTILITY(U,$J,358.3,21578,1,4,0)
 ;;=4^M32.10
 ;;^UTILITY(U,$J,358.3,21578,2)
 ;;=^5011753
 ;;^UTILITY(U,$J,358.3,21579,0)
 ;;=M32.9^^70^921^61
 ;;^UTILITY(U,$J,358.3,21579,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21579,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec
 ;;^UTILITY(U,$J,358.3,21579,1,4,0)
 ;;=4^M32.9
 ;;^UTILITY(U,$J,358.3,21579,2)
 ;;=^5011761
 ;;^UTILITY(U,$J,358.3,21580,0)
 ;;=M34.2^^70^921^63
 ;;^UTILITY(U,$J,358.3,21580,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21580,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,21580,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,21580,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,21581,0)
 ;;=M34.81^^70^921^64
 ;;^UTILITY(U,$J,358.3,21581,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21581,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,21581,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,21581,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,21582,0)
 ;;=M34.82^^70^921^65
 ;;^UTILITY(U,$J,358.3,21582,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21582,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,21582,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,21582,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,21583,0)
 ;;=M34.83^^70^921^66
 ;;^UTILITY(U,$J,358.3,21583,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21583,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,21583,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,21583,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,21584,0)
 ;;=M34.9^^70^921^67
 ;;^UTILITY(U,$J,358.3,21584,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21584,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,21584,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,21584,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,21585,0)
 ;;=J84.170^^70^921^16
 ;;^UTILITY(U,$J,358.3,21585,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21585,1,3,0)
 ;;=3^Interstitial Lung Dis w/ Progressive Fibrotic Phenotype in Dis Classd Elsewhere
 ;;^UTILITY(U,$J,358.3,21585,1,4,0)
 ;;=4^J84.170
 ;;^UTILITY(U,$J,358.3,21585,2)
 ;;=^5159208
 ;;^UTILITY(U,$J,358.3,21586,0)
 ;;=J84.178^^70^921^17
 ;;^UTILITY(U,$J,358.3,21586,1,0)
 ;;=^358.31IA^4^2
